With the entry into force of the Medical Device (MDR) and In Vitro Diagnostic Regulations (IVDR) on May the 25th, 2017, new requirements impacting Post Market Surveillance (PMS) have raised interrogations amongst Medical Device Manufacturers.
While a continuous evaluation and improvement of the process is at the very heart of this change, the Regulations introduces more incisive and prescriptive measures based on device risk level for both the MDR and IVDR.
The Post Market Surveillance requirements are pretty similar for both the Medical Device Regulation (MDR) and the In-Vitro Diagnostic Regulation (IVDR) and are located in Chapter 7 of both regulations. Chapter 7 points out to specific Annexes describing more in detail the provisions relating to this topic.
Join us on Wednesday, June 28th at 2:00 PM Eastern as LNE/G-MED North America Inc. will be hosting a free informative session on Post Market Surveillance requirements under the new European Medical Device Regulations.
The European Regulations on Medical Devices including Active Implantable Medical Devices (AIMD), and In Vitro Diagnostic (IVD) Medical Devices have been officially published on May 5th, 2017. Both entered into force on May the 25th, 2017.
The ISO 13485 standard represents a Quality Management System base for many regulatory schemes.
With the recent publication of the new Medical Device and In Vitro Diagnostic Regulations, the regulatory framework surrounding Medical Devices evolves and re-enforces the control of external parties (Suppliers, Subcontractors).
The newest revision of the ISO 13485 standard published in March 2016 aims in the very same direction.
Join us on Wednesday, May 24th at 2:00 PM Eastern as LNE/G-MED North America Inc. will be hosting a free informative session on Control of Critical Suppliers for Medical Devices: ISO 13485:2016 perspectives.
The Medical Device Regulation (MDR) and the In Vitro Diagnostics Regulation (IVDR) were initially proposed in 2008 when the EU Commission triggered a consultation on the community’s existing requirements covering medical devices. The plan was 1st released by the commission in 2012 to modify the EU’s medical device regulatory framework along with a proposed regulation replacing the EU’s current Medical Device Directive93/42/EEC, the EU’s directive on Active Implantable Medical Device90/385/EEC, and the In Vitro Diagnostic Directive 98/79/EEC.
Within the last few years, the Medical Device industry has witnessed a series of changes. The last one took place on April 5th, when the EU Parliament concluded years of tractions and discussions with the vote of the Medical Device and In Vitro Diagnostic Regulations.
What began in 2012 at the initiative of the European Commission came to an end during the plenary session of April 5th, 2017, with the adoption by the European Parliament of the new regulations on Medical and In Vitro Diagnostic Medical Devices (MDR and IVDR).
Join us on Wednesday, April 26th, 2017, 2 PM EDT as LNE/G-MED North America Inc. will be hosting a free informative session on the Medical Device and In Vitro Diagnostic regulations, the common changes and timelines introduced by the regulations, and what impact can manufacturers expect.